Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the upcoming CDMO Live 2025 conference scheduled for May 7-8, 2025, in Rotterdam, Netherlands.
Jackie Klecker, Executive Vice President of Quality and Development Services at Lifecore, will chair a discussion titled 'Quality as a Catalyst: Accelerating CDMO Success Through Quality Management' on Wednesday, May 7, 2025, at noon local time. The session will feature external quality leaders from the CDMO industry exploring approaches to transform quality management into a strategic driver of CDMO partnerships.
Klecker brings over 30 years of industry experience in quality, manufacturing, and development, including more than a decade overseeing Lifecore's quality assurance.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione completamente integrata di sviluppo e produzione a contratto (CDMO), ha annunciato la sua partecipazione alla prossima conferenza CDMO Live 2025, che si terrà il 7 e 8 maggio 2025 a Rotterdam, Paesi Bassi.
Jackie Klecker, Vicepresidente Esecutivo dei Servizi di Qualità e Sviluppo di Lifecore, presiederà una discussione intitolata 'La qualità come catalizzatore: accelerare il successo del CDMO attraverso la gestione della qualità' mercoledì 7 maggio 2025, a mezzogiorno ora locale. La sessione vedrà la partecipazione di leader esterni della qualità nel settore CDMO, che esploreranno approcci per trasformare la gestione della qualità in un motore strategico delle collaborazioni CDMO.
Klecker vanta oltre 30 anni di esperienza nel settore della qualità, produzione e sviluppo, inclusi più di dieci anni alla guida dell'assicurazione qualità di Lifecore.
Lifecore Biomedical (NASDAQ: LFCR), una organización completamente integrada de desarrollo y fabricación por contrato (CDMO), ha anunciado su participación en la próxima conferencia CDMO Live 2025, programada para los días 7 y 8 de mayo de 2025 en Rotterdam, Países Bajos.
Jackie Klecker, Vicepresidenta Ejecutiva de Servicios de Calidad y Desarrollo en Lifecore, dirigirá una discusión titulada 'La calidad como catalizador: acelerando el éxito del CDMO a través de la gestión de la calidad' el miércoles 7 de mayo de 2025, al mediodía hora local. La sesión contará con líderes externos de calidad de la industria CDMO que explorarán enfoques para transformar la gestión de la calidad en un motor estratégico de las asociaciones CDMO.
Klecker aporta más de 30 años de experiencia en calidad, manufactura y desarrollo, incluyendo más de una década supervisando el aseguramiento de calidad en Lifecore.
Lifecore Biomedical (NASDAQ: LFCR)는 완전 통합 계약 개발 및 제조 조직(CDMO)으로, 2025년 5월 7일부터 8일까지 네덜란드 로테르담에서 열리는 CDMO Live 2025 컨퍼런스에 참가할 예정임을 발표했습니다.
Lifecore의 품질 및 개발 서비스 담당 수석 부사장 Jackie Klecker는 2025년 5월 7일 수요일 현지 시간 정오에 '촉매로서의 품질: 품질 관리를 통한 CDMO 성공 가속화'라는 주제로 토론을 주재할 예정입니다. 이 세션에는 CDMO 업계 외부의 품질 리더들이 참여하여 품질 관리를 CDMO 파트너십의 전략적 동력으로 전환하는 방안을 모색할 것입니다.
Klecker는 품질, 제조 및 개발 분야에서 30년 이상의 경력을 보유하고 있으며, Lifecore의 품질 보증을 10년 이상 관리해 왔습니다.
Lifecore Biomedical (NASDAQ : LFCR), une organisation de développement et de fabrication sous contrat (CDMO) entièrement intégrée, a annoncé sa participation à la prochaine conférence CDMO Live 2025 prévue les 7 et 8 mai 2025 à Rotterdam, aux Pays-Bas.
Jackie Klecker, vice-présidente exécutive des services qualité et développement chez Lifecore, animera une discussion intitulée 'La qualité comme catalyseur : accélérer le succès des CDMO grâce à la gestion de la qualité' le mercredi 7 mai 2025 à midi, heure locale. La session réunira des responsables qualité externes de l'industrie CDMO qui exploreront des approches pour transformer la gestion de la qualité en un moteur stratégique des partenariats CDMO.
Klecker possède plus de 30 ans d'expérience dans l'industrie de la qualité, de la fabrication et du développement, dont plus de dix ans à superviser l'assurance qualité chez Lifecore.
Lifecore Biomedical (NASDAQ: LFCR), eine vollständig integrierte Vertragsentwicklungs- und Fertigungsorganisation (CDMO), hat ihre Teilnahme an der bevorstehenden CDMO Live 2025-Konferenz angekündigt, die am 7. und 8. Mai 2025 in Rotterdam, Niederlande, stattfindet.
Jackie Klecker, Executive Vice President für Qualitäts- und Entwicklungsdienste bei Lifecore, wird am Mittwoch, den 7. Mai 2025, um 12 Uhr Ortszeit eine Diskussion mit dem Titel 'Qualität als Katalysator: Beschleunigung des CDMO-Erfolgs durch Qualitätsmanagement' leiten. Die Sitzung wird externe Qualitätsleiter aus der CDMO-Branche umfassen, die Ansätze zur Umwandlung des Qualitätsmanagements in einen strategischen Treiber von CDMO-Partnerschaften erörtern.
Klecker verfügt über mehr als 30 Jahre Branchenerfahrung in den Bereichen Qualität, Fertigung und Entwicklung, darunter mehr als ein Jahrzehnt in der Leitung der Qualitätssicherung bei Lifecore.
- None.
- None.
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands.
During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development services, will chair a discussion featuring external quality leaders from the CDMO industry. The talk will explore approaches for transforming quality management from a potential bottleneck into a strategic driver of CDMO partnerships. Ms. Klecker is well-positioned to lead the discussion based on her more than 30 years of industry experience in quality, manufacturing, and development, including guiding Lifecore’s quality assurance for over a decade.
Details regarding the discussion are as follows:
- Quality as a Catalyst: Accelerating CDMO Success Through Quality Management
Chaired by Jackie Klecker, executive vice president, quality and development services, Lifecore Biomedical
Wednesday, May 7, 2025, Noon local time in Rotterdam
To learn more about the CDMO Live 2025 conference, please visit: https://pharmasource.global/events/cdmolive/
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
When and where is Lifecore Biomedical (LFCR) presenting at CDMO Live 2025?
What topic will Jackie Klecker discuss at CDMO Live 2025 for LFCR?
What is Jackie Klecker's role at Lifecore Biomedical (LFCR)?
How long has Jackie Klecker been managing quality assurance at LFCR?
What is the main focus of Lifecore Biomedical's (LFCR) presentation at CDMO Live 2025?
